•
Dec 26, 2020

Hologic Q1 2021 Earnings Report

Hologic had a strong start to fiscal 2021, driven by Diagnostics division and strengthened Breast Health and Surgical businesses.

Key Takeaways

Hologic's Q1 2021 revenue reached $1.61 billion, an 89.3% increase year-over-year, driven by strong performance in the Diagnostics division and growth in Breast Health and Surgical businesses. The company reported GAAP diluted EPS of $2.50 and non-GAAP diluted EPS of $2.86.

Revenue increased by 89.3% to $1.61 billion, with constant currency increase of 86.5%.

Organic revenue increased by 107.0%, or 104.0% in constant currency.

Worldwide molecular diagnostics revenue increased 457.6% to $995.3 million.

Cash flow from operations was $650.0 million, leading to debt repayment and stock repurchases.

Total Revenue
$1.61B
Previous year: $851M
+89.3%
EPS
$2.86
Previous year: $0.61
+368.9%
GAAP Gross Margin
73.3%
Non-GAAP Gross Margin
77.2%
Non-GAAP Operating Margin
60.2%
Gross Profit
$1.18B
Previous year: $434M
+172.1%
Cash and Equivalents
$869M
Previous year: $382M
+127.7%
Free Cash Flow
$618M
Previous year: $103M
+502.5%
Total Assets
$7.55B
Previous year: $6.31B
+19.6%

Hologic

Hologic

Hologic Revenue by Segment

Hologic Revenue by Geographic Location

Forward Guidance

Hologic expects strong financial performance to continue in the second quarter of fiscal 2021.

Positive Outlook

  • Revenue is expected to be between $1,500 million and $1,560 million.
  • Reported revenue increase is projected to be between 98.4% and 106.3%.
  • Constant currency revenue increase is expected to be between 93.9% and 101.9%.
  • Organic revenue increase is forecasted to be between 96.2% and 104.3%.
  • Non-GAAP EPS is expected to be between $2.56 and $2.68.

Revenue & Expenses

Visualization of income flow from segment revenue to net income